Jump to content

Ipsen

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 03:28, 26 November 2022 (Add: date, authors 1-1. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | #UCB_webform 768/2023). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For a list of people with the surname, see Ipsen (surname).
Ipsen S.A.
Company typePublic
Euronext: IPN
CAC Mid 60 Component
ISINFR0010259150 Edit this on Wikidata
IndustryPharmaceutical
Founded1929
HeadquartersParis, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
Products 
Revenue2,500,000,000 Euro (2020) Edit this on Wikidata
610,500,000 Euro (2020) Edit this on Wikidata
Number of employees
5,700
Websitewww.ipsen.com

Ipsen is a French pharmaceutical company headquartered in Paris, France.[1][self-published source] It is specialized in oncology, neuroscience and rare diseases.[1] It is publicly traded on the Euronext Paris as part of the SBF 120 index (2005).[1][2]

Ipsen, founded by Henri Beaufour in 1929, has 5,700 employees worldwide, and markets 20 drugs in 115 countries. The Beaufour family owns 57% of its shares and 73% of its voting rights,[3][self-published source] and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[4]

Overview

In 1954, the group launched Citrate de Betaïne which is used in the symptomatic treatment of dyspepsies. The two sons of Henri Beaufour, Albert and Gérard Beaufour, joined the company.[5]

In 1961, the first factory was opened in Dreux.[6]

In 1976, a research center was started in Milford in Massachusetts in the United States.[7] In 1977, the Smecta was launched.[5]

In 1983, the Ipsen Foundation was created, under the aegis of the Fondation de France.[8]

In 1992, Ipsen opened a subsidiary in China[9] and later, in 1994, in Russia.[citation needed]

In 2007, the group established a partnership with Galderma.[citation needed]

In 2013, Ipsen acquired the British company Syntaxin.[10]

In 2014, a laboratory was created with the CNRS in association with the French Alternative Energies and Atomic Energy Commission and the University of Rennes 1.[11]

In February 2015, the company announced Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R.[12]

in October 2016, European Commission approved Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.[13]

The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).[14]

In January 2017, Ipsen acquired some assets of Merrimack Pharmaceuticals, including Onivyde.[15]

In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion.[16] This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.[17]

In 2019, Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development.[18]

In July 2020, David Loew was appointed the General Manager and CEO in Ipsen.[19] In June 2022, Ipsen signed a definitive merger agreement to acquire Epizyme, a biopharmaceutical company, for $247 million.[20][21]

In February 2022, Ipsen announced that it was separating from its family health division after entering into exclusive negotiations with the French laboratory Mayoly Spindler. This sale could bring him 350 million euros.[22]

Research and development

In 2019, Ipsen's R&D expenditure totaled close to €388.8 million, representing more than 15.1% of group sales.[18] Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Les Ulis Courtaboeuf (France).[citation needed]

References

  1. ^ a b c "Profile & key figures". Ipsen. Archived from the original on 1 February 2013.
  2. ^ "Ipsen, "plus actif que jamais", prévoit des opérations de M&A". Investir (in French). 14 November 2018. Retrieved 9 June 2021.
  3. ^ 2015 Registration Document (PDF) (Report). 29 March 2016. Archived from the original (PDF) on 4 June 2016.
  4. ^ Challenges wealth ranking. Challenges.fr.
  5. ^ a b "Société d'Histoire de la Pharmacie – Le nouveau site de la SHP !" (in French). Retrieved 9 June 2021.
  6. ^ France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 9 June 2021.
  7. ^ pharma, Industrie (16 May 2005). "Résultats : Ipsen veut poursuivre sa politique d'alliances" (in French). {{cite journal}}: Cite journal requires |journal= (help)
  8. ^ "Homepage Ipsen". Fondation Ipsen. Retrieved 9 June 2021.
  9. ^ "France Chine : Informations, culture et tourisme en Chine". France Chine (in French). Retrieved 9 June 2021.
  10. ^ Nouvelle, L'Usine (15 July 2013). "Ipsen s'offre le spécialiste britannique des toxines botuliques Syntaxin" (in French). {{cite journal}}: Cite journal requires |journal= (help)
  11. ^ "Ipsen - CNRS Laboratoire Commun" (PDF).{{cite web}}: CS1 maint: url-status (link)
  12. ^ "Ipsen Gains Option to Buy Canbex Therapeutics for $6.8M+". 24 February 2015.
  13. ^ [1] European Commission approves Ipsen’s Cabometyx for treatment of advanced renal cell carcinoma
  14. ^ [2] Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx
  15. ^ Reuters Staff (9 January 2017). "France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal". Reuters. Retrieved 9 June 2021. {{cite news}}: |author= has generic name (help)
  16. ^ "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3..." 25 February 2019 – via uk.reuters.com.
  17. ^ "Ipsen completes acquisition of Clementia Pharmaceuticals". 18 April 2019 – via Pharmacy Business.
  18. ^ a b "IPSEN 2019 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT" (PDF). Ipsen. 2019. Retrieved 14 September 2021.{{cite web}}: CS1 maint: url-status (link)
  19. ^ "Ipsen mise sur l'innovation externe pour assurer sa croissance". Les Echos (in French). 1 December 2020. Retrieved 9 June 2021.
  20. ^ "Ipsen to buy biopharmaceutical company Epizyme for $247m". Pharmaceutical Technology. 27 June 2022. Retrieved 27 June 2022.
  21. ^ Kirby, Joshua. "Ipsen to acquire U.S.-based Epizyme for $247 million". MarketWatch. Retrieved 27 June 2022.
  22. ^ "Le laboratoire Ipsen se sépare du Smecta". LEFIGARO (in French). 11 February 2022. Retrieved 20 August 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ipsen&oldid=1123865604"